Valvular & structural heart disease
Effect of anti-fibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI): design and rationale of the Reduce-MFA DZHK25 trial
Study context
- Population
- Patients with severe aortic stenosis (AS) scheduled for TAVI with high baseline fibrotic burden (cardiac MRI (CMR)-derived ECV% ≥ 25.9%)enrolled, 153 randomized · enrolled 384 · randomized 153
- Participants
- 384 patients
- Planned comparison
- anti-fibrotic therapy vs Standard of Care alone
Methodological detailsPROBE design, design and rationale
- PROBE design
- Design and rationale
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Recruitment
- Enrolled
- 384
- Randomized
- 153
- Recruitment recently completed
Original publication
Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial. ESC Heart Fail. Published 12 May 2026. doi:10.
Summarised from the published abstract; every number is checked against it